Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the Rodman & Renshaw 13 th Annual Healthcare Conference at 2:25 p.m. EDT on September 12, 2011, in New York City. Dan Passeri, President and Chief Executive Officer, will provide an overview of Curis’ proprietary drug candidates including CUDC-101, a first-in-class EGFR/Her2/HDAC inhibitor, and CUDC-907, a dual PI3 kinase and HDAC inhibitor. Mr. Passeri will also discuss the status of Curis’ partnered programs including lead molecule vismodegib (GDC-0449, RG3616), an orally-administered small molecule Hedgehog pathway inhibitor that is being developed by Curis’ collaborator Genentech, and Debio 0932, an HSP90 inhibitor that is under development by Curis’ licensee Debiopharm. Mr. Passeri will also discuss other corporate activities. There will be a corresponding webcast of the presentation, which can be accessed by visiting: http://www.wsw.com/webcast/rrshq20/cris. The presentation will be archived shortly after the live event and available for 30 days following the conference. In addition, it will be available for 30 days on the Investor Relations section of the Curis website at www.curis.com. About Curis, Inc. Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs. For more information, visit Curis' website at www.curis.com.